VEGFA and hepatocellular carcinoma: Two phase III clinical trials [ORIENT-32 (Ren et al., 2021) and IMbrave150 (Finn et al., 2020a)] have shown a survival advantage of ICIs combined with anti-VEGF therapy compared with the standard treatment (sorafenib) for unresectable HCC.